RESUMEN
La resistencia a los antimicrobianos es un problema de salud pública a nivel mundial que va en aumento y se ve reflejada en la falta de eficacia de los tratamientos de infecciones bacterianas con antibióticos en humanos y en animales. El presente estudio tuvo como objetivo evaluar la resistencia a los antibióticos de cepas de Escherichia coli aisladas en carne de cerdo expendida en los mercados municipales de la ciudad de Guatemala. Se identificaron los antibióticos que presentaron mayor resistencia y mayor sensibilidad in vitro frente a las cepas de E. coli aisladas a partir de 76 muestras de carne de cerdo. Se realizó un muestreo aleatorio simple con afijación proporcional por mercado. Para la identificación de las cepas de E. coli se utilizó la prueba de IMViC y para evaluar la resistencia a los antimicrobianos se utilizó la prueba de Kirby Bauer empleando 9 antibióticos. Se aisló E. coli en el 55% (42/76) de las muestras. La resistencia en las 42 cepas aisladas fue: tetraciclina (83%) neomicina (50%) y sulfametoxasole + trimetoprim (50%). 83% de las cepas (35/42) fueron resistentes a 2 antibióticos y 50% (21/42) a 3 antibióticos o más. Se obtuvo mayor sensibilidad con ceftriaxona (91%), amikacina (83%), gentamicina (65%) y ácido nalidíxico (65%). Se concluye que existe resistencia a los antibióticos evaluados, lo que constituye un riesgo para la salud pública ya que se encuentra en cepas aisladas en un alimento para consumo humano.
Antimicrobial resistance is a global public health threat that is increasing and is reflected in the lack of efficacy of bacterial infection treatments with antibiotics in humans and animals. The objective of this study was to evaluate the resistance to antibiotics of Escherichia coli strains isolated from pork in the municipal markets of Guatemala City. Antibiotics with the highest resistance and those with the highest sensitivity in vitro against the strains of E. coli were evaluated. A simple random sampling was carried out with proportional allocation by market, and 76 samples were collected. IMViC test was used to identify the E. coli strains, and antibiotics resistance was evaluated using the Kirby Bauer with nine different antibiotics. E. coli was isolated in 55% (42/76) of the samples. Resistance was evaluated in the 42 isolates. Antibiotic resistance was detected to tetracycline (83%), neomycin (50%), and sulfamethoxazole + trimethoprim (50%). All isolates presented resistance to at least one antibiotic; it was determined that 83% (35/42) showed resistance to two antibiotics and 50% (21/42) showed resistance to three antibiotics or more. The sensitivity obtained was higher for ceftriaxone (91%), amikacin (83%), gentamicin (65%), and nalidixic acid (65%). In conclusion, antibiotic resistance was detected, which constitutes a risk to public health since it is found in isolated strains in food for human consumption.
Asunto(s)
Humanos , Animales , Farmacorresistencia Microbiana/efectos de los fármacos , Resistencia a la Kanamicina/efectos de los fármacos , Resistencia a la Tetraciclina/efectos de los fármacos , Resistencia al Trimetoprim/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Carne de Cerdo/microbiología , Ceftriaxona , Gentamicinas , Neomicina , Ácido Nalidíxico , Microbiología de Alimentos , Enrofloxacina , GuatemalaRESUMEN
Staphylococcus aureus has developed resistance to antimicrobials since their first use. The S. aureus major facilitator superfamily (MFS) efflux pump Tet(K) contributes to resistance to tetracyclines. The efflux pump diminishes antibiotic accumulation, and biofilm hampers the diffusion of antibiotics. None of the currently known compounds have been approved as efflux pump inhibitors (EPIs) for clinical use. In the current study, we screened clinically approved drugs for possible Tet(K) efflux pump inhibition. By performing in silico docking followed by in vitro checkerboard assays, we identified five azoles (the fungal ergosterol synthesis inhibitors) showing putative EPI-like potential with a fractional inhibitory concentration index of ≤0.5, indicating synergism. The functionality of the azoles was confirmed using ethidium bromide (EtBr) accumulation and efflux inhibition assays. In time-kill kinetics, the combination treatment with butoconazole engendered a marked increase in the bactericidal capacity of tetracycline. When assessing the off-target effects of the azoles, we observed no disruption of bacterial membrane permeability and polarization. Finally, the combination of azoles with tetracycline led to a significant eradication of preformed mature biofilms. This study demonstrates that azoles can be repurposed as putative Tet(K) EPIs and to reduce biofilm formation at clinically relevant concentrations. IMPORTANCE Staphylococcus aureus uses efflux pumps to transport antibiotics out of the cell and thus increases the dosage at which it endures antibiotics. Also, efflux pumps play a role in biofilm formation by the excretion of extracellular matrix molecules. One way to combat these pathogens may be to reduce the activity of efflux pumps and thereby increase pathogen sensitivity to existing antibiotics. We describe the in silico-based screen of clinically approved drugs that identified antifungal azoles inhibiting Tet(K), a pump that belongs to the major facilitator superfamily, and showed that these compounds bind to and block the activity of the Tet(K) pump. Azoles enhanced the susceptibility of tetracycline against S. aureus and its methicillin-resistant strains. The combination of azoles with tetracycline led to a significant reduction in preformed biofilms. Repurposing approved drugs may help solve the classical toxicity issues related to efflux pump inhibitors.
Asunto(s)
Antibacterianos/farmacología , Antifúngicos/farmacología , Azoles/farmacología , Proteínas Bacterianas/antagonistas & inhibidores , Proteínas de la Membrana/antagonistas & inhibidores , Resistencia a la Tetraciclina/efectos de los fármacos , Tetraciclina/farmacología , Antifúngicos/química , Azoles/química , Proteínas Bacterianas/química , Proteínas Bacterianas/metabolismo , Biopelículas/efectos de los fármacos , Proteínas de la Membrana/química , Proteínas de la Membrana/metabolismo , Simulación del Acoplamiento Molecular , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/metabolismo , Staphylococcus aureus/fisiologíaRESUMEN
The widely distributed seaweed Ulva fasciata has nutrient absorption abilities and can be used in the bioremediation of polluted maricultural environments. This study explored microbial community and antibiotic resistance gene (ARG) variation in mariculture sediments in response to different trace levels (10, 100, and 500 µg L-1) of oxytetracycline (OTC) and the presence of Ulva fasciata. The increase in OTC level promoted nutrient (NO3_-N and PO43--P) removal mainly due to Ulva fasciata adsorption. The abundances of the Euryarchaeota and Planctomycetes phyla in sediments were positively related to the increase in OTC stress, while a negative correlation occurred for the Proteobacteria phylum via metagenomic analysis. Compared with the control system, the increase rates of total ARGs were 3.90%, 7.36% and 13.42% at the OTC levels of 10, 100 and 500 µg L-1, respectively. OTC stress mainly favoured the collateral enrichment of non-corresponding polypeptide and MLS ARGs, mainly due to the enrichment of the phyla Planctomycetes and Euryarchaeota by the synergistic effect of OTC and nutrients. The results of quantitative PCR with tetracycline resistance genes (TRGs) (tetO, tetT, tetPB, tetW and otrA) and a horizontal transfer gene (intl1) demonstrated that all of genes had much higher gene numbers in sediments after 3 months of OTC stress than in those without OTC stress, which was strongly related to the variation in the phyla Bacteroidetes, Gemmatimonadetes and Acidobacteria. The significant correlation between intl1 and the target TRGs is indicative of the important role of the horizontal transfer of integron-resistant genes in the spread of TRGs.
Asunto(s)
Antibacterianos/toxicidad , Acuicultura , Farmacorresistencia Microbiana/genética , Genes Bacterianos , Ulva/fisiología , Bacterias/efectos de los fármacos , Biodegradación Ambiental , Integrones , Microbiota/efectos de los fármacos , Oxitetraciclina/análisis , Algas Marinas/efectos de los fármacos , Resistencia a la Tetraciclina/efectos de los fármacos , Ulva/efectos de los fármacosRESUMEN
Moraxella catarrhalis is considered an important, exclusively human respiratory tract pathogen which, along with Streptococcus pneumoniae and Haemophilus influenzae, is classified as one of the most frequent bacterial etiological factors causing upper respiratory tract infections. In this manuscript, we report the existence of five tetracycline-resistant M. catarrhalis strains with confirmed presence of tetracycline resistance tetB gene. The strains were isolated from children under the age of three with signs of upper respiratory tract infections. Our research also investigated the occurrence of virulence genes in these strains and involved the analysis of drug resistance to five antibiotic groups. It is the first description of clinical strains with confirmed presence of drug resistance tetB genes isolated in Europe.
Asunto(s)
Moraxella catarrhalis , Infecciones del Sistema Respiratorio , Resistencia a la Tetraciclina , Antibacterianos/farmacología , Niño , Europa (Continente) , Humanos , Pruebas de Sensibilidad Microbiana , Moraxella catarrhalis/genética , Polonia , Infecciones del Sistema Respiratorio/epidemiología , Resistencia a la Tetraciclina/efectos de los fármacos , Resistencia a la Tetraciclina/genéticaRESUMEN
Omadacycline and tigecycline MIC90 values were 2⯵g/mL and 0.25⯵g/mL, respectively, against Staphylococcus aureus carrying tet(M), whereas the minocycline, tetracycline, and doxycycline values wereâ¯>â¯8⯵g/mL. Similarly, omadacycline and tigecycline remained active against Enterococcus faecalis and Streptococcus pneumoniae harboring tet(L)and/or tet(M)(MIC90, 0.06-0.25⯵g/mL), whereas other tetracyclines were inactive (MIC90, >8⯵g/mL). Omadacycline and tigecycline remained more potent than minocycline, tetracycline, and doxycycline against Enterobacteriaceae carrying tet. This study demonstrates the effectiveness of modern tetracyclines, omadacycline, and tigecycline against isolates with tetracycline resistance genes.
Asunto(s)
Antibacterianos/farmacología , Resistencia a la Tetraciclina/efectos de los fármacos , Tetraciclinas/farmacología , Bacterias/efectos de los fármacos , Bacterias/genética , Bacterias/aislamiento & purificación , Proteínas Bacterianas/genética , Genotipo , Humanos , Pruebas de Sensibilidad Microbiana , Resistencia a la Tetraciclina/genética , Tigeciclina/farmacologíaRESUMEN
Recent emergence of high-level tigecycline resistance mediated by Tet(X3/X4) in Enterobacteriaceae undoubtably constitutes a serious threat for public health worldwide. Antibiotic adjuvant strategy makes antibiotic more effective against these resistant pathogens through interfering intrinsic resistance mechanisms or enhancing antibiotic actions. Herein, we screened a collection of drugs to identify compounds that are able to restore tigecycline activity against resistant pathogens. Encouragingly, we discovered that anti-HIV agent azidothymidine dramatically potentiates tigecycline activity against clinically resistant bacteria. Meanwhile, addition of azidothymidine prevents the evolution of tigecycline resistance in E. coli and the naturally occurring horizontal transfer of tet(X4). Evidence demonstrated that azidothymidine specifically inhibits DNA synthesis and suppresses resistance enzyme activity. Moreover, in in vivo infection models by Tet(X4)-expression E. coli, the combination of azidothymidine and tigecycline achieved remarkable treatment benefits including increased survival and decreased bacterial burden. These findings provide an effective regimen to treat infections caused by tigecycline-resistant Escherichia coli.
Asunto(s)
Antibacterianos/farmacología , Fármacos Anti-VIH/farmacología , Infecciones por Escherichia coli/tratamiento farmacológico , Proteínas de Escherichia coli/metabolismo , Escherichia coli/efectos de los fármacos , Peritonitis/tratamiento farmacológico , Resistencia a la Tetraciclina/efectos de los fármacos , Tetraciclina/farmacología , Zidovudina/farmacología , Animales , Antibacterianos/farmacocinética , Fármacos Anti-VIH/farmacocinética , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Escherichia coli/genética , Escherichia coli/metabolismo , Infecciones por Escherichia coli/microbiología , Proteínas de Escherichia coli/genética , Femenino , Regulación Bacteriana de la Expresión Génica , Ratones , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Peritonitis/microbiología , Tetraciclina/farmacocinética , Resistencia a la Tetraciclina/genética , Zidovudina/farmacocinéticaRESUMEN
KBP-7072 is a novel third-generation tetracycline (aminomethylcycline) antibacterial that overcomes common efflux and ribosomal protection resistance mechanisms that cause resistance in older-generation tetracyclines. KBP-7072 completed phase 1 clinical development studies for safety, tolerability, and pharmacokinetics (ClinicalTrials.gov identifier NCT02454361) and multiple ascending doses in healthy subjects (ClinicalTrials.gov identifier NCT02654626) in December 2015. Both oral and intravenous formulations of KBP-7072 are being developed. In this study, we evaluated the in vitro activities of KBP-7072 and comparator agents by CLSI document M07 (2018) broth microdilution against 531 recent geographically diverse and/or molecularly characterized Acinetobacter baumannii-A. calcoaceticus species complex (A. baumannii) isolates from the United States, Europe, Asia-Pacific (excluding China), and Latin America. A. baumannii isolates included carbapenem-resistant, colistin-resistant, tetracycline-resistant, and extended-spectrum-ß-lactamase (ESBL)- and metallo-ß-lactamase (MBL)-producing isolates. Overall, KBP-7072 (MIC50/90, 0.25/1 mg/liter) was comparable in activity to colistin (92.8%/92.8% susceptible [S] [CLSI/EUCAST]) against A. baumannii isolates, inhibiting 99.2% of isolates at ≤2 mg/liter and 97.6% of isolates at ≤1 mg/liter. KBP-7072 was equally active against A. baumannii isolates, including carbapenem-resistant, colistin-resistant, and tetracycline-resistant isolates, regardless of geographic location, and maintained activity against ESBL- and MBL-producing isolates. KBP-7072 outperformed comparator agents, including ceftazidime (40.3% S [CLSI]), gentamicin (48.2%/48.2% S [CLSI/EUCAST]), levofloxacin (39.5%/37.9% S [CLSI/EUCAST]), meropenem (42.0%/42.0% S [CLSI/EUCAST]), piperacillin-tazobactam (33.3% S [CLSI]), and all tetracycline-class comparator agents, which include doxycycline (67.3% S [CLSI]), minocycline (73.8% S [CLSI]), tetracycline (37.2% S [CLSI]), and tigecycline (79.5% inhibited by ≤2 mg/liter). The potent in vitro activity of KBP-7072 against recent geographically diverse, molecularly characterized, and drug-resistant A. baumannii isolates supports continued clinical development for the treatment of serious infections, including those caused by A. baumannii.
Asunto(s)
Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/farmacología , Tetraciclinas/farmacología , Acinetobacter baumannii/enzimología , Acinetobacter baumannii/genética , Carbapenémicos/farmacología , Colistina/farmacología , Farmacorresistencia Bacteriana/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Resistencia a la Tetraciclina/efectos de los fármacos , beta-Lactamasas/metabolismoRESUMEN
Omadacycline is a broad-spectrum aminomethylcycline approved in October 2018 by the U.S. Food and Drug Administration for treating acute bacterial skin and skin structure infections and community-acquired pneumonia as both an oral and intravenous once-daily formulation. In this report, the activities of omadacycline and comparators were tested against 49,000 nonduplicate bacterial isolates collected prospectively during 2016 to 2018 from medical centers in Europe (24,500 isolates, 40 medical centers [19 countries]) and the United States (24,500 isolates, 33 medical centers [23 states and all 9 U.S. census divisions]). Omadacycline was tested by broth microdilution following the methods in Clinical and Laboratory Standards Institute document M07 (Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, 11th ed., 2018). Omadacycline (MIC50/90, 0.12/0.25 mg/liter) inhibited 98.6% of Staphylococcus aureus isolates at ≤0.5 mg/liter, including 96.3% of methicillin-resistant S. aureus isolates and 99.8% of methicillin-susceptible S. aureus isolates. Omadacycline potency was comparable for Streptococcus pneumoniae (MIC50/90, 0.06/0.12 mg/liter), viridans group streptococci (MIC50/90, 0.06/0.12 mg/liter), and beta-hemolytic streptococci (MIC50/90, 0.12/0.25 mg/liter), regardless of species and susceptibility to penicillin, macrolides, or tetracycline. Omadacycline was active against all Enterobacterales tested (MIC50/90, 1/8 mg/liter; 87.5% of isolates were inhibited at ≤4 mg/liter) except Proteus mirabilis (MIC50/90, 16/>32 mg/liter) and indole-positive Proteus spp. (MIC50/90, 8/32 mg/liter) and was most active against Escherichia coli (MIC50/90, 0.5/2 mg/liter), Klebsiella oxytoca (MIC50/90, 1/2 mg/liter), and Citrobacter spp. (MIC50/90, 1/4 mg/liter). Omadacycline inhibited 92.4% of Enterobacter cloacae species complex and 88.5% of Klebsiella pneumoniae isolates at ≤4 mg/liter. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1 mg/liter), regardless of ß-lactamase status, and against Moraxella catarrhalis (MIC50/90, ≤0.12/0.25 mg/liter). The potent activity of omadacycline against Gram-positive and -negative bacteria indicates that omadacycline merits further study in serious infections in which multidrug resistance and mixed Gram-positive and Gram-negative bacterial infections may be a concern.
Asunto(s)
Antibacterianos/farmacología , Resistencia a la Tetraciclina/genética , Tetraciclinas/farmacología , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Europa (Continente) , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Humanos , Pruebas de Sensibilidad Microbiana , Neumonía Bacteriana/microbiología , Estudios Prospectivos , Vigilancia de Guardia , Enfermedades Cutáneas Bacterianas/microbiología , Resistencia a la Tetraciclina/efectos de los fármacos , Estados Unidos , Infecciones Urinarias/microbiologíaRESUMEN
The gut of aquatic animals was a significant niche for dissemination of antibiotic resistance genes (ARGs) and direct response of living conditions. In this study, the gut microbiota of goldfish Carassius auratus Linnaeus was sampled at 7 days and 21 days after treatment with tetracycline at 0.285 and 2.85 µg L-1 to investigate the influences on the microbial structure and antibiotic resistance. The proportion of tetracycline resistance bacteria was 1.02% in the control group, while increased to 23.00%, 38.43%, 62.05% in groups of high concentration for 7 days (H7), low concentration for 21 days (L21) and high concentration for 21 days (H21), respectively. Compared to the control group, the diversity of isolated Aeromonas spp. was decreased in the treatment groups and the minimal inhibitory concentration (MIC) of resistant isolates was enhanced from 32 to 256 µg mL-1 with the treatment of tetracycline in time- and dose-dependent manners. Furthermore, the abundance of most genes was increased in treatment groups and efflux genes mainly responded to the stress of tetracycline with an average level of 1.0 × 10-2. After treatment with tetracycline, the predominant species were changed both at phylum and genus levels. The present study explored the impact of tetracycline on gut microbiota of goldfish at environmentally realistic concentrations for the first time and our findings will provide a reference for characterizing the microbiome of fish in the natural environment.
Asunto(s)
Aeromonas/efectos de los fármacos , Microbioma Gastrointestinal/efectos de los fármacos , Carpa Dorada/microbiología , Resistencia a la Tetraciclina/genética , Tetraciclina/toxicidad , Aeromonas/clasificación , Aeromonas/genética , Aeromonas/aislamiento & purificación , Animales , Antibacterianos/toxicidad , Exposición a Riesgos Ambientales/efectos adversos , Genes Bacterianos , Pruebas de Sensibilidad Microbiana , Resistencia a la Tetraciclina/efectos de los fármacosRESUMEN
Tigecycline is a last-resort antibiotic that is used to treat severe infections caused by extensively drug-resistant bacteria. tet(X) has been shown to encode a flavin-dependent monooxygenase that modifies tigecycline1,2. Here, we report two unique mobile tigecycline-resistance genes, tet(X3) and tet(X4), in numerous Enterobacteriaceae and Acinetobacter that were isolated from animals, meat for consumption and humans. Tet(X3) and Tet(X4) inactivate all tetracyclines, including tigecycline and the newly FDA-approved eravacycline and omadacycline. Both tet(X3) and tet(X4) increase (by 64-128-fold) the tigecycline minimal inhibitory concentration values for Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii. In addition, both Tet(X3) (A. baumannii) and Tet(X4) (E. coli) significantly compromise tigecycline in in vivo infection models. Both tet(X3) and tet(X4) are adjacent to insertion sequence ISVsa3 on their respective conjugative plasmids and confer a mild fitness cost (relative fitness of >0.704). Database mining and retrospective screening analyses confirm that tet(X3) and tet(X4) are globally present in clinical bacteria-even in the same bacteria as blaNDM-1, resulting in resistance to both tigecycline and carbapenems. Our findings suggest that both the surveillance of tet(X) variants in clinical and animal sectors and the use of tetracyclines in food production require urgent global attention.
Asunto(s)
Bacterias , Proteínas Bacterianas/genética , Oxigenasas de Función Mixta/genética , Plásmidos/genética , Resistencia a la Tetraciclina/genética , Tigeciclina/farmacología , Animales , Antibacterianos/metabolismo , Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Bacterias/genética , Proteínas Bacterianas/metabolismo , Elementos Transponibles de ADN , Humanos , Carne/microbiología , Pruebas de Sensibilidad Microbiana , Oxigenasas de Función Mixta/metabolismo , Resistencia a la Tetraciclina/efectos de los fármacos , Tigeciclina/metabolismoRESUMEN
The expression of bacterial virulence factors is controlled in response to host or environmental factors and most virulence genes are not expressed under laboratory conditions. Investigations of molecular structures and cellular functions of bacterial virulence factors demand systems for experimentally controlled expression. We describe a simple and robust system that is based on the tetA promoter and the cognate repressor TetR. Expression under control of PtetA can be induced by non-antibiotic derivatives of tetracycline such as anhydrotetracycline (AHT). Tet-on expression cassettes can be used to replace native promoters of chromosomal genes or operons of interest. Tet-on plasmids allow episomal expression in homologous or heterologous host organisms. We demonstrate the application of Tet-on systems for the controlled induction of flagella assembly and motility, and for surface expression of adhesins of the chaperone/usher family of enteropathogenic Escherichia coli and autotransporter adhesins of Yersinia enterocolitica in Salmonella enterica and E. coli. Since inducer AHT can easily cross bacterial envelopes and mammalian cell membranes, the system can also be applied to control virulence genes in intracellular bacteria. We demonstrate the controlled synthesis, translocation and function of effector proteins of the type III secretion system of intracellular S. enterica.
Asunto(s)
Antiportadores/metabolismo , Proteínas Bacterianas/metabolismo , Escherichia coli Enteropatógena/patogenicidad , Regulación Bacteriana de la Expresión Génica , Regiones Promotoras Genéticas/genética , Salmonella enterica/patogenicidad , Yersinia enterocolitica/patogenicidad , Adhesinas Bacterianas/genética , Adhesinas Bacterianas/metabolismo , Antiportadores/genética , Proteínas Bacterianas/genética , Escherichia coli Enteropatógena/genética , Flagelos/genética , Flagelos/metabolismo , Regulación Bacteriana de la Expresión Génica/efectos de los fármacos , Células HeLa , Humanos , Operón/efectos de los fármacos , Operón/genética , Regiones Promotoras Genéticas/efectos de los fármacos , Salmonella enterica/genética , Resistencia a la Tetraciclina/efectos de los fármacos , Resistencia a la Tetraciclina/genética , Tetraciclinas/farmacología , Virulencia/efectos de los fármacos , Virulencia/genética , Yersinia enterocolitica/genéticaRESUMEN
NetF-producing type A Clostridium perfringens, a pathotype of C. perfringens, causes necrotizing enteritis in neonatal foals and necrotizing and hemorrhagic enteritis in dogs. Recent core genome multilocus sequence typing study revealed that netF+ C. perfringens strains belong to two distinct clonal populations (clonal complexes I and II). There are no reports on susceptibility to antimicrobial drugs of isolates from this pathotype. The susceptibility to 13 different antimicrobial drugs of 49 netF+ strains recovered from foals or dogs with necrotizing enteritis in Canada, the United States, and Switzerland was assessed using a commercial microdilution panel designed for anaerobic human pathogens. All isolates were highly susceptible to 12 antimicrobial agents, including all beta-lactams tested, such as penicillin G and ampicillin, as well as clindamycin, chloramphenicol, and metronidazole. The isolates consistently presented a reduced susceptibility or resistance to tetracycline, which was associated with previously described tetracycline resistance genes. Clonal complex I isolates (n = 41) possessed the tetA408(P) gene, whereas clonal complex II isolates (n = 8) possessed the tetA(P)-tetB(P) genes and were more likely to be fully resistant.
Asunto(s)
Antibacterianos/farmacología , Infecciones por Clostridium/tratamiento farmacológico , Clostridium perfringens/efectos de los fármacos , Clostridium perfringens/genética , Resistencia a la Tetraciclina/efectos de los fármacos , Resistencia a la Tetraciclina/genética , Tetraciclina/farmacología , Animales , Canadá , Infecciones por Clostridium/microbiología , ADN Bacteriano/genética , Perros , Caballos , Tipificación de Secuencias Multilocus/métodos , Suiza , Estados Unidos , beta-Lactamas/farmacologíaRESUMEN
Manure application contributes to the increased environmental burden of antibiotic resistance genes (ARGs). We investigated the response of tetracycline (tet) resistance genes and bacterial taxa to manure application amended with tetracyclines over two months. Representative tetracyclines (oxytetracycline, chlorotetracycline and doxycycline), tet resistance genes (tet(M), tet(O), tet(W), tet(S), tet(Q) and tet(X)) and bacterial taxa in the untreated soil, +manure, and +manure+tetracyclines groups were analyzed. The abundances of all tet resistance genes in the +manure group were significantly higher than those in the untreated soil group on day 1. The abundances of all tet resistance genes (except tet(Q) and tet(X)) were significantly lower in the +manure group than those in the +manure+tetracyclines group on day 30 and 60. The dissipation rates were higher in the +manure group than those in the +manure+tetracyclines group. Disturbance of soil bacterial community composition imposed by tetracyclines was also observed. The results indicated that tetracyclines slowed down the dissipation of tet resistance genes in arable soil after manure application. Application of manure amended with tetracyclines may provide a significant selective advantage for species affiliated to the taxonomical families of Micromonosporaceae, Propionibacteriaceae, Streptomycetaceae, Nitrospiraceae and Clostridiaceae.
Asunto(s)
Antibacterianos/farmacología , Bacterias/clasificación , Estiércol/microbiología , Microbiología del Suelo , Resistencia a la Tetraciclina/genética , Tetraciclina/farmacología , Bacterias/efectos de los fármacos , Genes Bacterianos , Consorcios Microbianos/genética , Suelo/química , Resistencia a la Tetraciclina/efectos de los fármacosRESUMEN
The presence of antibiotic resistant bacteria (ARB) in wastewater was investigated and the role of wastewater treatment plants (WWTPs) in promoting or limiting antibiotic resistance was assessed. Escherichia coli (E. coli) and total heterotrophic bacteria (THB) resistance to ampicillin, chloramphenicol and tetracycline was monitored in three WWTPs located in Milan urban area (Italy), differing among them for the operating parameters of biological process, for the disinfection processes (based on sodium hypochlorite, UV radiation, peracetic acid) and for the discharge limits to be met. Wastewater was collected from three sampling points along the treatment sequence (WWTP influent, effluent from sand filtration, WWTP effluent). Antibiotic resistance to ampicillin was observed both for E. coli and for THB. Ampicillin resistant bacteria in the WWTP influents were 20-47% of E. coli and 16-25% of THB counts. A limited resistance to chloramphenicol was observed only for E. coli, while neither for E. coli nor for THB tetracycline resistance was observed. The biological treatment and sand filtration led to a decrease in the maximum percentage of ampicillin-resistant bacteria (20-29% for E. coli, 11-21% for THB). However, the conventionally adopted parameters did not seem adequate to support an interpretation of WWTP role in ARB spread. Peracetic acid was effective in selectively acting on antibiotic resistant THB, unlike UV radiation and sodium hypochlorite. The low counts of E. coli in WWTP final effluents in case of agricultural reuse did not allow to compare the effect of the different disinfection processes on antibiotic resistance.
Asunto(s)
Farmacorresistencia Microbiana/genética , Eliminación de Residuos Líquidos/estadística & datos numéricos , Aguas Residuales/microbiología , Contaminación Química del Agua/estadística & datos numéricos , Ampicilina , Antibacterianos/farmacología , Bacterias/efectos de los fármacos , Bacterias/genética , Cloranfenicol , Desinfección , Ambiente , Escherichia coli/efectos de los fármacos , Filtración , Procesos Heterotróficos , Italia , Aguas del Alcantarillado/microbiología , Tetraciclina/farmacología , Resistencia a la Tetraciclina/efectos de los fármacos , Aguas Residuales/estadística & datos numéricosRESUMEN
Biodegradation of antibiotic residues in the environment by microorganisms may lead to the generation of antibiotic resistance genes (ARGs), which are of great concern to human health. The aim of this study was to determine whether there is a relationship between the ability to degrade antibiotic doxycycline (DOX) and the development of resistance genes in microorganisms. We isolated and identified ten bacterial strains from a vegetable field that had received long-term manure application as fertilizer and were capable of surviving in a series of DOX concentrations (25, 50, 80, and 100mg/L). Our results showed no evidential correlation between DOX degradation ability and the development of resistance genes among the isolated microorganisms that had high DOX degradation capability (P > 0.05). This was based on the fact that Escherichia sp. and Candida sp. were the most efficient bacterial strains to degrade DOX (92.52% and 91.63%, respectively), but their tetracycline resistance genes showed a relatively low risk of antibiotic resistance in a 7-day experiment. Moreover, the tetM of the ribosomal protection protein genes carried by these two preponderant bacteria was five-fold higher than that carried by other isolates (P < 0.05). Pearson correlations between the Ct/C0 of DOX and tet resistance genes of three isolates, except for Escherichia sp. and Candida sp., showed remarkable negative correlations (P < 0.05), mainly because tetG markedly increased during the DOX degradation process. Our results concluded that the biodegradation of antibiotic residues may not necessarily lead to the development of ARGs in the environment. In addition, the two bacteria that we isolated, namely, Escherichia sp. and Candida sp., are potential candidates for the engineering of environmentally friendly bacteria.
Asunto(s)
Doxiciclina/toxicidad , Farmacorresistencia Microbiana/efectos de los fármacos , Microbiología del Suelo/normas , Contaminantes del Suelo/toxicidad , Drogas Veterinarias/toxicidad , Biodegradación Ambiental , Candida/efectos de los fármacos , Candida/genética , China , Relación Dosis-Respuesta a Droga , Farmacorresistencia Microbiana/genética , Escherichia/efectos de los fármacos , Escherichia/genética , Fertilizantes , Genes Bacterianos , Estiércol/microbiología , Resistencia a la Tetraciclina/efectos de los fármacos , Resistencia a la Tetraciclina/genéticaRESUMEN
Although tetracyclines are an important class of antibiotics for use in agriculture and the clinic, their efficacy is threatened by increasing resistance. Resistance to tetracyclines can occur through efflux, ribosomal protection, or enzymatic inactivation. Surprisingly, tetracycline enzymatic inactivation has remained largely unexplored, despite providing the distinct advantage of antibiotic clearance. The tetracycline destructases are a recently discovered family of tetracycline-inactivating flavoenzymes from pathogens and soil metagenomes that have a high potential for broad dissemination. Here, we show that tetracycline destructases accommodate tetracycline-class antibiotics in diverse and novel orientations for catalysis, and antibiotic binding drives unprecedented structural dynamics facilitating tetracycline inactivation. We identify a key inhibitor binding mode that locks the flavin adenine dinucleotide cofactor in an inactive state, functionally rescuing tetracycline activity. Our results reveal the potential of a new tetracycline and tetracycline destructase inhibitor combination therapy strategy to overcome resistance by enzymatic inactivation and restore the use of an important class of antibiotics.
Asunto(s)
Antibacterianos/metabolismo , Inhibidores Enzimáticos/farmacología , Legionella longbeachae/efectos de los fármacos , Legionella longbeachae/enzimología , Resistencia a la Tetraciclina/efectos de los fármacos , Tetraciclina/metabolismo , Antibacterianos/química , Antibacterianos/farmacología , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/química , Flavina-Adenina Dinucleótido/metabolismo , Legionella longbeachae/metabolismo , Modelos Moleculares , Conformación Molecular , Relación Estructura-Actividad , Tetraciclina/química , Tetraciclina/farmacologíaRESUMEN
In recent years, the influence of new materials like nanoparticles in the water environment on biological substances has been widely studied. Antibiotic resistance genes (ARGs) represent a new type of pollutant in the environment. Graphene oxide (GO), as a nano material, because of its unique structure, may have an impact on antibiotic resistance bacteria (ARB) and ARGs; however the research in this area is rarely reported. Therefore, this study mainly investigated the effects of GO on bacterial antibiotic resistance. The results showed that GO had a limited effect on ARB inactivation. A high concentration of GO (>10 mg/L) can damage resistant plasmids to reduce bacterial resistance to antibiotics, but low concentrations of GO (<1 mg/L) led to almost no damage to the plasmid. However, all tested concentrations of GO promoted the conjugative transfer from 1to over 3 folds, with low concentrations and high concentration (1-10 and 100 mg/L) of GO samples the least promoted. The overall effect of GO on antibiotic resistance needs further investigation.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Genes Bacterianos/efectos de los fármacos , Grafito/farmacología , Antibacterianos/química , Farmacorresistencia Bacteriana/genética , Escherichia coli/genética , Grafito/química , Viabilidad Microbiana/genética , Óxidos/química , Óxidos/farmacología , Plásmidos , Tetraciclina/farmacología , Resistencia a la Tetraciclina/efectos de los fármacos , Resistencia a la Tetraciclina/genéticaRESUMEN
Annually, millions pounds of antibiotics are released unmetabolized into environment along with animal wastes. Accumulation of antibiotics in soils could potentially induce the persistence of antibiotic resistant bacteria. Antibiotics such as tetracyclines and tetracycline-resistant bacteria have been previously detected in fields fertilized with animal manure. However, little is known about the accumulation of tetracyclines and the development of tetracycline resistance in semi-arid soils. Here we demonstrate that continuous land application with swine effluent, containing trace amounts of chlortetracycline, does not necessarily induce tetracycline resistance in soil bacteria. Based on the testing of more than 3,000 bacteria isolated from the amended soils, we found no significant increase in the occurrence and level of chlortetracycline resistant bacteria in soils after 15 years of continuous swine effluent fertilization. To account for a possible transfer of tetracycline-resistant bacteria originated from the swine effluent to soils, we analyzed two commonly found tetracycline resistant genes, tet(O) and tet(M), in the swine effluent and fertilized soils. Both genes were present in the swine effluent, however, they were not detectable in soils applied with swine effluent. Our data demonstrate that agronomic application of manure from antibiotic treated swine effluent does not necessarily result in the development of antibiotic bacterial resistance in soils. Apparently, concentrations of chlortetracycline present in manure are not significant enough to induce the development of antibiotic bacterial resistance.
Asunto(s)
Bacterias/efectos de los fármacos , Estiércol/microbiología , Microbiología del Suelo , Resistencia a la Tetraciclina/efectos de los fármacos , Agricultura , Animales , Antibacterianos/farmacología , Clortetraciclina/análisis , Clortetraciclina/farmacología , Fertilizantes , Pruebas de Sensibilidad Microbiana , Oklahoma , Contaminantes del Suelo/análisis , Porcinos , Tetraciclina/farmacología , Tetraciclinas/farmacologíaRESUMEN
Antibiotic resistance genes (ARGs), as emerging environmental contaminants, have become a threat to human health. Recent studies have demonstrated that the effluent from wastewater treatment plants is a significant point source of ARGs released into the environment. In this study, we investigated the effectiveness of coagulation technology in the removal of ARGs from treated wastewater. Specifically, we measured the removal of five ARGs (two sulfonamide resistance genes, sulI and sulII, and three tetracycline resistance genes, tetO, tetW and tetQ) and the class 1 integron intI1 gene via the application of two coagulants: FeCl3 and polyferric chloride (PFC). Moreover, the removal of dissolved organic carbon (DOC), NH3N and total phosphorus (TP) in the coagulation process was investigated. The coagulation process effectively removed ARGs from the effluent with 0.5-log to 3.1-log reductions. Significant removal correlations were observed between dissolved NH3N and DOC, intI1 and sulI, sulII and tetO, sulII and tetW, and tetO and tetW, implying that the co-removal of DOC, dissolved NH3N, the intI1 gene and different ARGs played an important role in ARG loss during coagulation with Fe-based coagulants. These results indicate that coagulation may play a promising role in ARG reduction in wastewater treatment plants.